Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-U.S. to send 4 mln doses of AstraZeneca vaccine to Mexico, Canada in loan deal -official

Thu, 18th Mar 2021 16:59

(Adds Psaki comment)

By Jeff Mason

WASHINGTON, March 18 (Reuters) - The United States plans to
send roughly 4 million doses of AstraZeneca's COVID-19 vaccine
that it is not using to Mexico and Canada in loan deals with the
two countries, an administration official told Reuters on
Thursday.

Mexico will receive 2.5 million doses of the vaccine and
Canada is to receive 1.5 million doses, the official said.

"We're lending a portion of our releasable doses of
AstraZeneca vaccine," the official said on condition of
anonymity. "We only put the virus behind us if we're helping our
global partners."

White House spokeswoman Jen Psaki confirmed the plan, first
reported by Reuters, to send doses to Mexico and Canada. "It is
not fully finalized yet but it is our aim," she told a daily
briefing.

The Biden administration has come under pressure from allies
worldwide to share vaccines, particularly from AstraZeneca,
which is authorized for use in other countries but not yet in
the United States.

AstraZeneca has millions of doses made in a U.S.
facility, and has said that it would have 30 million shots ready
at the beginning of April. The company's shares rose slightly on
the news.

The deal to share the vaccine, which is still being
finalized, does not affect President Joe Biden's plans to have
vaccine available for all adults in the United States by the end
of May, the official said. It does not reduce the supply of
available vaccine in the United States.

The deal is likely to be announced publicly in the coming
days.

Two officials said the vaccine would be delivered in "short
order" once the deal was completed, but they declined to give a
more specific timetable.

The "releasable" vaccines are ready to be used once they
arrive. Under the deal, the United States will share doses with
Mexico and Canada now with the understanding that they will pay
the United States back with doses in return. The official said
that would take place later this year.

The United States had no plans to share the vaccine with
other countries at this time, he said.

"They are our neighbors, they are our partners," the
official said about Mexico and Canada. Mexican President Andres
Manuel Lopez Obrador had requested the vaccine previously. The
official said the countries were in touch about the vaccine
loan. "We've been working through the diplomatic channels," he
said.

Reports of blood disorders have prompted more than a dozen
nations to suspend use of AstraZeneca's vaccine but on Thursday
the EU's drug watchdog said that after an investigation it is
still convinced the benefits of that vaccine outweigh the risks.

Biden has said if the United States has a surplus of
vaccine, it will share it with the rest of the world. The White
House has focused on vaccinating people in the United States,
which has seen more than 530,000 people die from virus.

The country was getting prepared to roll out the AstraZeneca
vaccine domestically if it gets authorization from the U.S. Food
and Drug Administration, the official said.

The official noted that the United States has pledged $4
billion to the COVAX vaccine facility that aims to deliver
coronavirus vaccines to poor countries.

The United States does not need the AstraZeneca shots to
meet its target of having enough doses for all U.S. adults by
the end of May.

The three authorized vaccine makers – Pfizer Inc/BioNTech
SE, Moderna Inc, and Johnson & Johnson – have promised to
deliver nearly 500 million doses to the United States by then.
(Reporting by Jeff Mason; additional reporting by Trevor
Hunnicutt and Caroline Humer; Editing by Heather Timmons and
Alistair Bell)

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.